Clinical Trial: A randomized, double-blind, placebo-controlled, parallel-group phase III trial to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in patients with chronic rhinosinusitis with nasal polyps (China)

China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized, double-blind, placebo-controlled, parallel-group phase III trial to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in patients with chronic rhinosinusitis with nasal polyps'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135735

Registration Time: 2026/11/02

Type: Interventional study

Primary Sponsor: Eye & ENT hospital of Fudan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348523

Published by HT Digital Content Services with permission from Health Daily Digest....